Oncology Therapeutics Start-Up Oncologie Gets US$80M For Clinical-Stage Programs

Login to View

China and US-based oncology therapeutics start-up Oncologie announced on Monday that it has closed a US$80 million series B round of financing led by Hong Kong-based life sciences-focused investment firm Nan Fung Life Sciences, and Pivotal BioVentures Partners China, a member of Nan Fung Life Sciences.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in